International Majors Invest 170 Million NOK in Norwegian Hydrogen Mem-Tech
10.5.2022 13:01:00 EEST | Business Wire | Press release
AP Ventures, Yara Growth Ventures, Shell Ventures, Saudi Aramco Energy Ventures and SINTEF Venture are putting their trust and investment into Hydrogen Mem-Tech (HMT). HMT´s palladium membrane technology separates hydrogen from bio and natural gas.
"We are proud and incredibly humbled to have secured what will be one of the largest capital investments in an early-stage Norwegian tech company in recent years”, says Thomas Reinertsen, CEO of Hydrogen Mem-Tech.
The company has developed a technology where clean hydrogen is produced from bio and natural gas, while CO2 and other residual gases are captured to be utilized or sequestered. The HMT palladium membrane technology builds on more than 20 years of research from SINTEF, and it has been extensively tested and piloted over several years.
“We are very pleased to have secured investors with a strong mix of industrial and financial expertise. I´m certain that our new investors will help deploy our technology out into the world.” said Thor Egil Five, Chairman of the board at Hydrogen Mem-Tech.
“We are delighted to have led the investment round for Hydrogen Mem-Tech with a strong group of co-investors. As an established investor in the hydrogen value chain, we understand the exciting potential of this technology to unlock decarbonization opportunities across hard to abate industry and mobility.” said Andrew Hinkly, Managing Partner at AP Ventures.
Yara´s investment company for start-ups, ‘Yara Growth Ventures’, are among the new investors.
“We believe that this promising technology developed in Norway will contribute to trigger new Norwegian industry and help increase the use of hydrogen and ammonia. This is one of several investments we plan to make in Norway”, says Stian Nygaard, Investment Director at Yara Growth Ventures.
“As a company, we have an ambition to accelerate the hydrogen economy. HMT’s technology enables the adoption of hydrogen and ammonia and fuels the progress society needs for a cleaner energy future. We are excited to help them take the next steps and explore the many potential applications across industries”, said Bilal Ahmad, Venture Principal at Shell Ventures.
“For Saudi Aramco Energy Ventures this investment into HMT is very strategic. Hydrogen and carbon capture technologies are of the highest importance to Aramco, and we look forward to working with HMT to use their unique gas separation membranes and realizing the benefits they bring”, says Richard Riggs, Investment Director at Saudi Aramco Energy Ventures.
“We are very happy to be able to partner with this highly respected and professional venture investor group to bring HMT one step closer to commercial success. The technology behind the technology is licensed from SINTEF and our investment in HMT supports our key mandate - Technology for a better society, where we invest in companies with SINTEF based technology.” says Asle Jostein Hovda, Investment Director at SINTEF Venture.
Read more at: https://hydrogen-mem-tech.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220510005726/en/
Contact information
Thomas Reinertsen, CEO
(+47) 930 90 494
thomas.reinertsen@hydrogen-mem-tech.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Medical University of Graz Enrolls First Patient in DEEPER CHALLENGE Trial Evaluating Spur ® Peripheral Retrievable Scaffold System in a Select CLTI Cohort2.7.2026 14:00:00 EEST | Press release
Reflow Medical, Inc. announces that the Medical University of Graz has enrolled the first patient in the DEEPER CHALLENGE clinical trial. This investigator-initiated, single-center, single-arm, prospective study, supported by a grant, investigates early vessel recoil following below-the-knee treatment using the Spur® Peripheral Retrievable Scaffold System in combination with a commercially available drug-coated balloon. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260701995624/en/ The study investigates early vessel recoil following below-the-knee treatment using the Spur® Peripheral Retrievable Scaffold System in combination with a commercially available drug-coated balloon. The study plans to enroll up to 40 patients with chronic limb-threatening ischemia (CLTI) across two distinct cohorts: patients with diabetes and patients with end-stage renal disease receiving hemodialysis for at least six months, with women comprisi
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)2.7.2026 13:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to eight newly hired non-executive employees. The equity awards were granted on July 1, 2026 and consisted of options to purchase an aggregate of 63,685 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 30,300 shares. The options have an exercise price per share equal to $13.29, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted sh
Infobip Launches PitchMate — An AI Fan Companion for Global Football2.7.2026 13:00:00 EEST | Press release
Global AI-first cloud communications platform Infobip launched PitchMate, a new AI-powered conversational agent that brings football fans closer to the action of the world’s biggest football tournament. Purpose-built for the global football audience, PitchMate joins the TGR Haas F1 Team RaceMate — Infobip’s AI fan engagement solution for the TGR Haas F1 Team — in demonstrating how conversational AI is transforming fan engagement across sports worldwide. RaceMate, launched last April for this year’s motorsport season, is an AI agent on WhatsApp and Apple Messages for Business that puts TGR Haas F1 Team fans at the center of the action. It delivers real-time race data, personalized content, team radio highlights, trivia, and native multilingual support, turning passive viewers into active participants through natural, human-like conversations across every race weekend. Since its launch, RaceMate has reached users in more than 60 countries, achieving more than 40,000 messages exchanged wi
Besins Healthcare Strengthens Innovation Capabilities with Acquisition of UniD Manufacturing, a Specialist in Long-Acting Drug Delivery Technologies2.7.2026 12:00:00 EEST | Press release
Besins Healthcare, a global pharmaceutical company specializing in hormonal health, today announced the acquisition of UniD Manufacturing, a Belgium-based pharmaceutical development and manufacturing company with more than 20 years of recognized expertise in long-acting drug delivery technologies.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260701779777/en/ Besins Healthcare Strengthens Innovation Capabilities with Acquisition of UniD Manufacturing, a Specialist in Long-Acting Drug Delivery Technologies This acquisition brings together two highly compatible areas. Besins Healthcare brings deep expertise in hormone therapies for women’s and men’s health, including treatments such as Estrogel®/Oestrogel® (estradiol)2 and Utrogestan®3 (micronized progesterone) for women, and Androgel®/Testogel®4 (testosterone) for men. UniD contributes advanced capabilities in technologies that can enable more differentiated, less frequentl
ROYC Selected by Slättö as Structuring and Platform Solution for Luxembourg Feeder Fund2.7.2026 11:45:00 EEST | Press release
ROYC, a leading global structuring and platform provider, today announced that Slättö, a Nordic private markets real estate firm, has selected ROYC to establish and manage a Luxembourg-domiciled feeder fund designed to efficiently aggregate individual subscriptions from professional investors. The Luxembourg-domiciled vehicle will be fully structured and administered on ROYC’s proprietary platform, delivering investors a seamless digital experience with real-time portfolio access, automated reporting, and efficient global distribution. ROYC streamlines onboarding and governance, standardizes legal documentation, and broadens access to capital. “Private markets are undergoing a structural shift as global banks and wealth platforms increasingly seek efficient access to high-quality private equity strategies. By combining our deep structuring expertise with ROYC’s digital operating infrastructure, we enable leading managers like Slättö to launch investor-ready vehicles rapidly while deliv
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom